Your browser is no longer supported. Please, upgrade your browser.
Settings
NERV [NASD]
Minerva Neurosciences, Inc.
Index- P/E38.45 EPS (ttm)0.06 Insider Own0.80% Shs Outstand42.70M Perf Week-3.88%
Market Cap94.82M Forward P/E- EPS next Y-0.74 Insider Trans-3.56% Shs Float41.13M Perf Month-7.85%
Income1.90M PEG- EPS next Q0.33 Inst Own70.90% Short Float6.14% Perf Quarter-36.10%
Sales41.20M P/S2.30 EPS this Y102.60% Inst Trans2.53% Short Ratio7.60 Perf Half Y-35.36%
Book/sh1.23 P/B1.81 EPS next Y-236.40% ROA3.00% Target Price- Perf Year-82.23%
Cash/sh0.60 P/C3.73 EPS next 5Y- ROE4.20% 52W Range1.81 - 15.22 Perf YTD-4.70%
Dividend- P/FCF- EPS past 5Y15.30% ROI3.50% 52W High-85.34% Beta1.13
Dividend %- Quick Ratio8.70 Sales past 5Y- Gross Margin- 52W Low23.20% ATR0.13
Employees11 Current Ratio8.70 Sales Q/Q- Oper. Margin- RSI (14)34.09 Volatility5.55% 5.20%
OptionableYes Debt/Eq0.00 EPS Q/Q77.60% Profit Margin4.70% Rel Volume9.63 Prev Close2.29
ShortableYes LT Debt/Eq0.00 EarningsMay 12 BMO Payout0.00% Avg Volume332.13K Price2.23
Recom2.20 SMA20-8.29% SMA50-19.13% SMA200-27.99% Volume3,197,985 Change-2.62%
Jun-08-20Reiterated H.C. Wainwright Buy $20 → $10
May-14-20Initiated BTIG Research Buy $23
Oct-02-19Reiterated Chardan Capital Markets Buy $17
Sep-25-19Initiated Chardan Capital Markets Buy $17
Sep-18-19Initiated William Blair Outperform
May-31-19Initiated H.C. Wainwright Buy
Sep-01-17Initiated Citigroup Buy $11
Mar-06-17Resumed Jefferies Buy $17
May-12-16Resumed Jefferies Buy
May-11-21 04:15PM  
May-05-21 05:10PM  
Apr-07-21 08:46AM  
Apr-05-21 09:31AM  
Mar-08-21 12:30PM  
07:30AM  
05:30AM  
Mar-06-21 10:57AM  
Mar-01-21 08:30AM  
Feb-08-21 02:30PM  
01:20PM  
12:30PM  
11:30AM  
11:13AM  
11:00AM  
09:43AM  
06:20AM  
12:45AM  
Feb-07-21 01:12PM  
10:30AM  
Feb-06-21 01:10PM  
10:00AM  
07:15AM  
Feb-05-21 09:15PM  
09:00PM  
07:00PM  
04:35PM  
04:00PM  
01:00PM  
12:15PM  
11:45AM  
11:00AM  
10:35AM  
09:39AM  
Feb-04-21 02:00PM  
12:30PM  
12:28PM  
11:00AM  
06:25AM  
Feb-03-21 10:20PM  
09:00PM  
07:00PM  
05:30PM  
04:23PM  
03:15PM  
02:30PM  
01:45PM  
12:32PM  
11:00AM  
06:07AM  
Feb-02-21 11:28PM  
01:40PM  
01:00PM  
12:05PM  
11:00AM  
11:00AM  
09:05AM  
08:00AM  
03:23AM  
Feb-01-21 04:50PM  
04:00PM  
Jan-31-21 10:20AM  
05:05AM  
05:00AM  
Jan-29-21 04:45PM  
03:58PM  
02:40PM  
01:25PM  
11:31AM  
10:00AM  
09:30AM  
08:00AM  
06:30AM  
Jan-28-21 12:30PM  
12:00PM  
Jan-27-21 07:40PM  
07:00PM  
06:30PM  
06:00PM  
03:40PM  
03:00PM  
Jan-26-21 03:30PM  
02:33PM  
11:50AM  
11:00AM  
Jan-25-21 11:15AM  
10:39AM  
09:00AM  
08:00AM  
Jan-24-21 10:50AM  
07:30AM  
Jan-23-21 01:10PM  
Jan-22-21 06:20PM  
05:30PM  
Jan-21-21 06:38PM  
05:09PM  
12:59PM  
12:00PM  
11:00AM  
09:30AM  
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, a compound in Phase III clinical trial for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Reilly Joseph H.SVP & Chief Operating OfficerDec 16Sale2.643,2288,52231,747Dec 16 08:37 PM
Race GeoffEVP, CFO & CBODec 16Sale2.646,19016,342211,354Dec 16 08:31 PM
Luthringer RemyCEODec 16Sale2.641,3003,43266,490Dec 16 08:29 PM
Ahlholm Frederick WSVP, Chief Accounting OfficerDec 16Sale2.641,8454,87110,039Dec 16 08:29 PM
VAN HEEK G JANDirectorSep 10Buy2.977,00020,79020,333Sep 11 05:13 PM
Ahlholm Frederick WSVP, Chief Accounting OfficerMay 26Sale15.008,339125,0856,884May 27 04:43 PM